在CDKN1A (p21) 的31号编码子的多态性作为预测因子,用于治疗贝瓦齐祖马布在多形质母细胞瘤治疗
Wen-Yu Cheng1,2,3,4, Chiung-Chyi Shen5,6,7, Yea-Jiuen Liang5
1Department of Minimally Invasive Skull Base Neurosurgery, Neurological Institute, Taichung Veterans General Hospital, Taichung city, Taiwan. wycheng07@yahoo.com.tw.
BMC cancer
|September 20, 2023
概括
CDKN1A c.93C>A 多态可能会影响质母细胞瘤的发展. 一些基因型显示,使用贝瓦西祖马布治疗与化学放射治疗相结合,生存率有所改善.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 药物基因组学 药物基因组学
背景情况:
- 质母细胞瘤 (GBM) 是一种具有攻击性的脑瘤,具有挑战性的手术切除.
- CDKN1A (p21,Waf-1) 是细胞循环停止,分化和亡的关键调节者.
- CDKN1A中的遗传变异与癌症易感性和治疗反应有关.
研究的目的:
- 为了识别CDKN1A的多态变体,特别是c.93C>A (codon 31 Ser31Arg).
- 为了研究这种多态性对贝瓦西祖马布治疗结果在质母细胞瘤患者的影响.
主要方法:
- 在台湾对139名中国GBM患者的回顾性研究.
- 使用PCR-RFLP分析进行CDKN1Ac.93C>A多态的基因定型.
- 使用无条件逻辑回归来计算赔率比率和置信区间的统计分析.
主要成果:
- 编码子31多态的分布是Ser/Ser (23.02%),Arg/Arg (27.34%) 和Ser/Arg (49.64%). 编码子31多态的分布是Ser/Ser (23.02%),Arg/Arg (27.34%) 和Ser/Arg (49.64%) 的.
- CDKN1A c.93C>A多态性与整体GBM患者存活率没有直接关联.
- 患有Arg/Arg和Arg/Ser基因型的患者在结合化疗放射治疗 (CCRT) 和贝瓦齐祖马布治疗时比单独使用CCRT治疗时的生存率有所改善.
结论:
- CDKN1A c.93C>A多态体在质母细胞瘤的发展中起作用.
- 这种多态性可能预测贝瓦西祖马布治疗对GBM患者的反应.
- 这些发现表明,基于CDKN1A基因型,可以对治疗结果进行早期预后.
关键词:
贝瓦西祖马布 (bevacizumab) 是一种药物.CDKN1A c.93C > A CDKN1A c.93C > A CDKN1A c.93C > A CDKN1A c.93C > A CDKN1A c.93C > A CDKN1A c.93C > A CDKN1A c.93C > A CDKN1A c.93C > A CDKN1A c.93C > A CDKN1A c.93C > A CDKN1A c.93C > A CDKN1A c.93C > A CDKN1A c.93C > A CDKN1A c.93C > A CDKN1A c.93C > A CDKN1A质母细胞瘤 (glioblastoma) 是一个这就是PCRRFLP.多态性多态性多态性
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:07Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K